Overview

A Study to Evaluate the Bioavailability of Teduglutide Administered Subcutaneously by Syringe Injection Versus Pen Injector in Healthy Adult Participants

Status:
Completed

Trial end date:
2021-07-16

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the bioavailability of teduglutide administered as a single subcutaneous (SC) fixed dose (depending upon participant weightband assignment) delivered by a syringe injection and the same fixed dose delivered by the pen injector in healthy participants.

Phase:

Phase 1

Details

Lead Sponsor:

Shire

Collaborator:

Takeda Development Center Americas, Inc.

Treatments:

Teduglutide